Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
Resverlogix is now ranked among the top 10 undervalued stocks in the Healthcare sector on the Toronto Stock Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below). The healthcare sector contains companies in biotechnology, pharmaceuticals, hospitals, home and long-term care as well as related medical equipment manufacturers and suppliers.
All data provided as-at market close March 05, 2023. The list is sorted by stocks with the greatest percentage difference between valuation and price. Resverlogix Resverlogix Corp is a clinical stage biotechnology company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease. Resverlogix is listed under RVX on the Toronto Stock Exchange.
| Symbol | Name | Close Price | Shares Outstanding | P/E | P/B | Cash per Share | Net Cash per Share |
|---|---|---|---|---|---|---|---|
| RVX-T | Resverlogix | 0.15 | 0 | 0 | 0 | 0 | 0 |
| TMD-T | Titan Medical | 0.27 | 0 | 0 | 0 | 0 | 0 |
| APS-T | Aptose Biosciences | 0.79 | 0 | 0 | 0 | 0 | 0 |
| AEZS-T | AEterna Zentaris | 4.56 | 0 | 0 | 0 | 0 | 0 |
| TBP-T | Tetra Bio Pharma | 0.03 | 0 | 0 | 0 | 0 | 0 |
| CWEB-T | Charlottes Web Holdings | 0.52 | 0 | 0 | 0 | 0 | 0 |
| CRON-T | Cronos Group | 2.83 | 0 | 0 | 0 | 0 | 0 |
| INCR-U-T | Intercure | 2.52 | 0 | 12.5 | 0 | 0 | 0 |
| VIVO-T | VIVO Cannabis | 0.03 | 0 | 0 | 0 | 0 | 0 |
| WLLW-T | Willow Biosciences | 0.1 | 0 | 0 | 0 | 0 | 0 |
More about Resverlogix
Stocks in this category are held primarily for capital appreciation.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
